At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 112 enrolled
Drug / intervention
Tofacitinib +1 moredrug
Likely dose
Tofacitinib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study To Assess The Immune Response Following Administration Of Zoster Vaccine To Subjects With Rheumatoid Arthritis Receiving Tofacitinib (Cp-690,550) Or Placebo With Background Methotrexate Treatment
In Brief
A Phase 2 clinical trial evaluating Tofacitinib and Placebo for Rheumatoid Arthritis. Completed, enrolled 112 participants across 36 sites.
Detailed Summary
This study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartJun 2014
Primary CompletionJun 2015
Study CompletionJul 2015
TodayJul 2026
First PostedMay 28, 2014
Enrollment StartJun 1, 2014
Primary CompletionJun 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.1 years ago
Interventions
Tofacitinibdrug
5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
Placebodrug
Placebo tablets twice daily with background methotrexate for 12 weeks